[Neoadjuvant therapeutic principles guided by response prediction and evaluation].
Only patients with a clinical and pathohistological response to neoadjuvant therapy have a significantly improved survival. Therefore the identification of predictors for response and procedures for the early identification of nonresponders appear to be mandatory. Preliminary data of biochemical investigations of target enzymes for several cytostatics (e.g. TS, ERCC1) appear to be promising. Early changes of the tumor metabolism in the FDG-PET enable the identification of nonresponders with a negative predictive value of 88-95%. In near future these findings should lead to consequences in the design and realization of clinical studies.
Fink
U
U
Chirurgische Klinik und Poliklinik, Technische Universität München, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 München.
Ott
K
K
Weber
W
W
Siewert
J R
JR
D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D019788:Fluorodeoxyglucose F18; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D020360:Neoadjuvant Therapy; D009703:Nucleoside-Phosphate Kinase / Q000235:genetics; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18; D009703:Nucleoside-Phosphate Kinase; C020093:dTMP kinase
Neoadjuvante Therapieprinzipien orientiert an Responseprädiktion und Evaluation.